Advertisement
AZN vs LLY
Which Stock Would AI Choose? AstraZeneca (AZN) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- Eli Lilly (LLY) holds a commanding market position with a $776 billion market capitalization, dwarfing AstraZeneca's (AZN) $291 billion.
- LLY has delivered stronger year-to-date returns of 19.07% compared to AZN's 2.40%, reflecting robust demand for its GLP-1 therapies.
- Both stocks trade at premium valuations, with LLY's price-to-earnings (P/E) ratio at 37.88 versus AZN's 28.67.
- Recent oncology-focused deals bolster LLY's pipeline, while AZN advances with approvals like subcutaneous SAPHNELO.
- Analysts remain bullish on both, with average price targets implying upside: $1,202 for LLY and $212 for AZN.
- Upcoming Q1 earnings for both could shift sentiment amid broader healthcare sector volatility.
Introduction
AstraZeneca (AZN) and Eli Lilly (LLY) represent two pillars of the global pharmaceutical industry, with AZN emphasizing oncology and rare diseases, and LLY leading in diabetes, obesity, and neuroscience treatments. This stock comparison analyzes their recent market performance, growth drivers, and positioning in a sector facing patent cliffs, regulatory scrutiny, and innovation demands. Traders seeking momentum plays and long-term investors eyeing pipeline strength will find value in understanding their relative momentum, valuations, and catalysts. As healthcare evolves with AI-driven drug discovery and blockbuster therapies, evaluating AZN versus LLY highlights key trade-offs in stability versus high-growth potential.
AZN Overview and Recent Performance
AstraZeneca (AZN), a UK-based biopharmaceutical giant, focuses on oncology, cardiovascular, renal, metabolism, respiratory, and immunology (CVRM, R&I, and rare disease) franchises. Trading around $187.50 recently, the stock has shown resilience with a year-to-date gain of 2.40% and 37.12% over one year, amid a 52-week range of $132.32 to $212.71. In recent weeks, sentiment has been supported by positive phase III trial results from the I CAN study and U.S. approval for subcutaneous self-administration of SAPHNELO (anifrolumab) for systemic lupus erythematosus. Market activity reflects steady oncology demand and anticipation for Q1 earnings, tempering minor pullbacks in volatile sessions. Broader influences include partnerships and regulatory wins, positioning AZN as a defensive play in healthcare.
LLY Overview and Recent Performance
Eli Lilly (LLY), a U.S. powerhouse, drives growth through diabetes/obesity drugs like Mounjaro and Zepbound, alongside oncology and immunology portfolios. The stock, near $868 recently, has outperformed year-to-date with 19.07% returns, despite short-term volatility within a 52-week range of $623.78 to $1,133.95. Recent market activity features oncology expansions via the $2.3 billion acquisition of Ajax Therapeutics for hematology assets and a partnership with Profluent on AI-designed recombinases. Analyst optimism persists amid prescription data fluctuations, with Q1 earnings looming as a key catalyst. These developments underscore LLY's aggressive pipeline buildout in high-demand areas.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available—specifically 25 selected out of 351 total bots designed to trade thousands of tickers across various market conditions. These bots employ diverse strategies, including short-term scalping, swing trading, and long-term trend following, with performance metrics like win rates often ranging from 60-80%, average returns of 20-50% annually, and drawdowns managed below 15% in top performers. Tailored to current volatility, sectors like healthcare feature prominently, offering automated signals for stocks such as AZN and LLY. Explore these bots to align with your risk profile and timeframe for data-driven trading edges.
Head-to-Head Comparison
AZN and LLY both anchor the pharma sector but diverge in scale and focus: LLY's obesity franchise fuels explosive revenue growth, contrasting AZN's diversified oncology and rare disease stability. Recent momentum favors LLY's 19% YTD surge over AZN's modest gains, though LLY exhibits higher volatility from competition in GLP-1 drugs. Risk factors include patent expirations for AZN and manufacturing pressures for LLY, with LLY's higher P/E signaling growth premiums. Market sentiment tilts toward LLY's acquisitions versus AZN's regulatory milestones, balancing trade-offs in growth versus defensive positioning.
Tickeron AI Verdict
Tickeron's AI currently leans toward LLY for its superior year-to-date momentum, aggressive oncology expansions, and bullish analyst consensus, suggesting higher probability of near-term upside amid healthcare tailwinds. AZN offers relative stability and attractive valuation, appealing for risk-averse positioning ahead of earnings. Observable trends favor LLY's catalysts in a probabilistic sense.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Hold and LLY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green whileLLY’s FA Score has 4 green FA rating(s).
- AZN’s FA Score: 2 green, 3 red.
- LLY’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 4 TA indicator(s) are bullish while LLY’s TA Score has 3 bullish TA indicator(s).
- AZN’s TA Score: 4 bullish, 4 bearish.
- LLY’s TA Score: 3 bullish, 5 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а -4.03% price change this week, while LLY (@Pharmaceuticals: Major) price change was -5.37% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
AZN is expected to report earnings on Jul 27, 2026.
LLY is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AZN | LLY | AZN / LLY | |
| Capitalization | 271B | 980B | 28% |
| EBITDA | 20.1B | 36.2B | 56% |
| Gain YTD | 90.286 | 2.570 | 3,513% |
| P/E Ratio | 26.34 | 39.03 | 68% |
| Revenue | 60.4B | 72.2B | 84% |
| Total Cash | 7.68B | 5.28B | 145% |
| Total Debt | 33.9B | 43.4B | 78% |
AZN | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 8 | 14 | |
SMR RATING 1..100 | 41 | 12 | |
PRICE GROWTH RATING 1..100 | 39 | 23 | |
P/E GROWTH RATING 1..100 | 61 | 87 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (12) in the Pharmaceuticals Major industry is in the same range as LLY (20). This means that AZN’s stock grew similarly to LLY’s over the last 12 months.
AZN's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is in the same range as LLY (14). This means that AZN’s stock grew similarly to LLY’s over the last 12 months.
LLY's SMR Rating (12) in the Pharmaceuticals Major industry is in the same range as AZN (41). This means that LLY’s stock grew similarly to AZN’s over the last 12 months.
LLY's Price Growth Rating (23) in the Pharmaceuticals Major industry is in the same range as AZN (39). This means that LLY’s stock grew similarly to AZN’s over the last 12 months.
AZN's P/E Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as LLY (87). This means that AZN’s stock grew similarly to LLY’s over the last 12 months.
| AZN | LLY | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 43% | 4 days ago 69% |
| Stochastic ODDS (%) | 4 days ago 62% | 4 days ago 76% |
| Momentum ODDS (%) | 4 days ago 52% | 4 days ago 67% |
| MACD ODDS (%) | 4 days ago 60% | 4 days ago 64% |
| TrendWeek ODDS (%) | 4 days ago 45% | 4 days ago 60% |
| TrendMonth ODDS (%) | 4 days ago 43% | 4 days ago 68% |
| Advances ODDS (%) | 17 days ago 57% | 14 days ago 69% |
| Declines ODDS (%) | 4 days ago 45% | 4 days ago 56% |
| BollingerBands ODDS (%) | 4 days ago 64% | 4 days ago 54% |
| Aroon ODDS (%) | 6 days ago 48% | 4 days ago 71% |
Advertisement
AZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AZN | 1D Price Change % | ||
|---|---|---|---|---|
| AZN | 100% | -1.66% | ||
| BIIB - AZN | 48% Loosely correlated | -1.05% | ||
| LLY - AZN | 44% Loosely correlated | -1.21% | ||
| GILD - AZN | 39% Loosely correlated | -1.35% | ||
| MRK - AZN | 30% Poorly correlated | -1.36% | ||
| NVS - AZN | 28% Poorly correlated | -2.52% | ||
More | ||||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AMGN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AMGN could also see price increases.